UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy

Frontiers in oncology, 2022-10, Vol.12, p.1019925-1019925

2022

Volltextzugriff (PDF)

Nomogram to Predict Distant Metastasis Probability for Pathological Complete Response Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy

Cancer management and research, 2021-01, Vol.13, p.4751-4761

2021

Volltextzugriff (PDF)

通常型膵癌に対する術前化学放射線療法にてpCRを得たが肺再発を来した一例

膵臓, 2014, Vol.29(2), pp.234-240

2014

Volltextzugriff (PDF)

The Response, Operability, and Type of Surgery Following Neoadjuvant Chemotherapy in Sudanese Patients with Locally Advanced Breast Cancer

Sudan journal of medical sciences, 2018-09, Vol.13 (3), p.219

2018

Volltextzugriff (PDF)

A Case of Right Stage IIA Non-small-cell Lung Cancer Confirmed to Have Shown a Pathological Complete Response After Chemoradiotherapy Followed by Durvalumab for Contralateral Left IIIA Non-small-cell Lung Cancer

Haigan, 2023/08/20, Vol.63(4), pp.302-307

2023

Volltextzugriff (PDF)

Predictive factors of achievement pathological complete response at neoadjuvant chemotherapy of primary operable breast cancer

Sovremennaia onkologiia : zhurnal kafedry onkologii RMAPO dlia nepreryvnogo poslediplomnogo obrazovaniia, 2017, Vol.19 (1), p.24-29

2017

Volltextzugriff (PDF)

Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy (N-1 Study, Phase II Trial) in Patients With Operable Breast Cancer

Clinical breast cancer, 2024-07, Vol.24 (5), p.e350-e359.e2

2024

Volltextzugriff (PDF)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial

Annals of oncology, 2024-07

2024

Volltextzugriff (PDF)

An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma

Annals of surgery, 2022-11, Vol.276 (5), p.799-805

2022

Volltextzugriff (PDF)

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)

Frontiers in immunology, 2022-06, Vol.13, p.849984-849984

2022

Volltextzugriff (PDF)

Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy

European journal of surgical oncology, 2019-12, Vol.45 (12), p.2289-2294

2019

Volltextzugriff (PDF)

Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer

Annals of surgery, 2021-07, Vol.274 (1), p.162-169

2021

Volltextzugriff (PDF)

Zoledronic-acid plus neoadjuvant therapy is associated with provoking outcomes in Her2-positive breast cancer

Asian journal of surgery, 2024-07

2024

Volltextzugriff (PDF)

Factors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non-metastatic muscle invasive urothelial bladder cancer

Northwestern Medical Journal, 2023-10, Vol.3 (3), p.139-146

2023

Volltextzugriff (PDF)

The impact of pathological complete response on survival in patients with breast cancer and occurrence in different intrinsic subtypes: A retrospective observational study

Cancer research, statistics, and treatment (Online), 2023-04, Vol.6 (2), p.191-199

2023

Volltextzugriff (PDF)

Risk stratification according to stage and pathology1

Breast (Edinburgh), 2019-11, Vol.48, p.S23-S25

Regan, Meredith M.

2019

Volltextzugriff (PDF)

Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy

World journal of surgery, 2024-07, Vol.48 (7), p.1700-1709

2024

Volltextzugriff (PDF)

MRI-based delta-radiomics are predictive of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Academic radiology, 2021-11, Vol.28, p.S95-S104

2021

Volltextzugriff (PDF)

Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy

Clinical breast cancer, 2024-08

2024

Volltextzugriff (PDF)

Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study

Annals of surgery, 2023-02, Vol.277 (2), p.259-266

2023

Volltextzugriff (PDF)

Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients

Breast (Edinburgh), 2019-04, Vol.44, p.33-38

2019

Volltextzugriff (PDF)

Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer

World journal of gastroenterology : WJG, 2019-01, Vol.25 (1), p.118-137

2019

Volltextzugriff (PDF)

The Deepest Extent of Acellular Mucin Pools in Resected Locally Advanced Rectal Cancer With Pathological Complete Response After Preoperative Chemoradiotherapy: A Hidden Killer?

The American journal of surgical pathology, 2023-07, Vol.47 (7), p.812-818

2023

Volltextzugriff (PDF)

Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery

Frontiers in oncology, 2020-08, Vol.10, p.1398-1398

2020

Volltextzugriff (PDF)

Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy

European journal of cancer (1990), 2022-11, Vol.176, p.30-40

2022

Volltextzugriff (PDF)

1 – 25 von 1.088

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(951)
Mit Volltextzugriff
(977)

Publikationsform

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Frontiers In Oncology
(48)
Breast Cancer Research And Treatment
(39)
Cancers
(38)
Bmc Cancer
(26)
Frontiers In Immunology
(21)
European Journal Of Surgical Oncology
(20)
Breast
(19)
Breast Cancer
(18)
Gan To Kagaku Ryoho
(18)
Annals Of Oncology
(16)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(6)
... seit 90 Tagen
(23)

Menü

Weitere Dienste

Einstellungen

Clinical N3 is an independent risk factor of recurrence for breast cancer patients achieving pathological complete response and near-pathological complete response after neoadjuvant chemotherapy

Nomogram to Predict Distant Metastasis Probability for Pathological Complete Response Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy

通常型膵癌に対する術前化学放射線療法にてpCRを得たが肺再発を来した一例

The Response, Operability, and Type of Surgery Following Neoadjuvant Chemotherapy in Sudanese Patients with Locally Advanced Breast Cancer

A Case of Right Stage IIA Non-small-cell Lung Cancer Confirmed to Have Shown a Pathological Complete Response After Chemoradiotherapy Followed by Durvalumab for Contralateral Left IIIA Non-small-cell Lung Cancer

Predictive factors of achievement pathological complete response at neoadjuvant chemotherapy of primary operable breast cancer

Long-Term Outcomes of S-1 Combined With Low-Dose Docetaxel as Neoadjuvant Chemotherapy (N-1 Study, Phase II Trial) in Patients With Operable Breast Cancer

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial

An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)

Clinical and pathological predictors of recurrence in breast cancer patients achieving pathological complete response to neoadjuvant chemotherapy

Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer

Zoledronic-acid plus neoadjuvant therapy is associated with provoking outcomes in Her2-positive breast cancer

Factors predicting pathological complete response to neoadjuvant chemotherapy in patients diagnosed with non-metastatic muscle invasive urothelial bladder cancer

The impact of pathological complete response on survival in patients with breast cancer and occurrence in different intrinsic subtypes: A retrospective observational study

Risk stratification according to stage and pathology1

Risk factors for recurrence of esophageal squamous cell carcinoma after pathological complete response to neoadjuvant therapy followed by esophagectomy

MRI-based delta-radiomics are predictive of pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Analysis of Factors Associated With Pathological Complete Response in Patients With HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy

Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study

Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients

Nomograms for predicting pathological response to neoadjuvant treatments in patients with rectal cancer

The Deepest Extent of Acellular Mucin Pools in Resected Locally Advanced Rectal Cancer With Pathological Complete Response After Preoperative Chemoradiotherapy: A Hidden Killer?

Development and Validation of a Radiomics Nomogram Model for Predicting Postoperative Recurrence in Patients With Esophageal Squamous Cell Cancer Who Achieved pCR After Neoadjuvant Chemoradiotherapy Followed by Surgery

Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy

Suchergebnisse filtern